PacBio Q4 revenue rises 14% driven by strong consumable sales

Pacific Biosciences of California

12/02/2026 21:27

Overview

Life science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable sales

Adjusted net income for Q4 beat analyst expectations

Company completed sale of short-read sequencing assets, strengthening balance sheet

Outlook

Company plans to launch SPRQ-Nx to lower sequencing costs in 2026

PacBio aims to drive growth with strengthened balance sheet post asset sale

Company did not provide specific financial guidance for 2026

Result Drivers

RECORD CONSUMABLE SALES - Consumable revenue reached an all-time high, contributing significantly to Q4 revenue growth

ASSET SALE - Completed sale of short-read sequencing assets, strengthening balance sheet

DECLINE IN REVIO PLACEMENTS - Revio system placements decreased compared to the previous year

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted Net Income
Beat
-$37.60 mln
-$44.30 mln (4 Analysts)
Q4 Adjusted Gross Profit
$17.80 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, about 8.7% above its February 11 closing price of $1.84

Press Release: ID:nGNX8cG9QQ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)